Dog, I agree with you that KPMG is a quality firm with a much higher recognition value for future investors in Cardiogenics.

I am surprised with the change as I would imagine KPMG's fees will be larger than Cohn's. If true and as Dr G has been carefully managing expenses why would he make this change? Seeing the glass as half full, I choose to believe he is staging the company for positive news regards the head-to-head study and the assessment of the paramagnetic beads by Abbott and the MTA companies.

Ante